The FDA proposed a rule to streamline drug establishment registration for distributed manufacturing networks operating under a hub-and-spoke model. If finalized, distributed manufacturing establishments could register as a single entity, reducing administrative burden while tightening the agency’s ability to track changes through a streamlined update process and advance notification for unit moves.